Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Russia Rejects Abbott Laboratories Plan To Buy Petrovax-Reuters


Saturday, 20 Apr 2013 08:57am EDT 

Reuters reported that Russia's government commission on foreign investment has turned down U.S. group Abbott Laboratories' request to buy Russian vaccine maker Petrovax, the head of Russia's competition regulator said. Igor Artemyev, head of the Federal Anti-Monopoly Service (FAS) said the decision was made in order to protect the country's national security interests and took into account international experience. Abbott Laboratories applied for permission to buy Petrovax last year and according to media reports the deal was valued at $280 million.